Molecular modeling study of the multidrug resistance modifiers cis- and trans-flupentixol

Pharmazie

Volumn 52, Issue 9, 1997, Pages 679-685

  Wiese, Michael ^a,c   Pajeva, I K ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

^c Inst F Pharmazeutische Chemie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUPENTIXOL; GLYCOPROTEIN P;

ARTICLE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPHILICITY; MEMBRANE BINDING; MOLECULAR MODEL; MULTIDRUG RESISTANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; QUANTUM CHEMISTRY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

DRUG RESISTANCE, MULTIPLE; ELECTROCHEMISTRY; FLUPENTHIXOL; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANE LIPIDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; P-GLYCOPROTEIN; QUANTUM THEORY; STEREOISOMERISM;

EID: 0031406294     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kessel, D.: Resistance to Antineoplastic Drugs, CRC Press, p. 1, Boca Raton, Florida, 1989
2. Ford, J. M.; Hait, W. N.: Pharmacol. Rev. 42, 156 (1990)
3. Kellen, J. A.: Anticancer Res. 13, 959 (1993)
4. Ford, J.: Hematology/Oncology Clinics of North America 9(2), 337 (1995)
5. Cornwall, M. M.; Pastan, I.; Gottesman, M. M.; in: Roninson, I. B. (Ed.): Molecular and Cellular Biology of Multidrug Resistance in Tumour Cells, p. 229, Plenum, New York, London 1991
6. Yang, J.-M.; Chin, K.-V; Hait, W. N.: Cancer Res. 56, 3490 (1996)
7. Pajeva, I. K.; Wiese, M.: Quant. Struct.-Act. Relat. 16, 1 (1997)
8. Seydel, J. K.; Coats, E. A.; Cordes, H.-P.; Wiese, M.: Arch. Pharm. 327, 601 (1994)
9. Pajeva, I. K.; Wiese, M.; Cordes, H.-P.; Seydel, J. K.: J. Cancer Res. Clin. One. 122, 27 (1996)
10. Ford, J. M.; Prozialeck, W. C.; Hait, W. N.: Mol, Pharmacol. 35, 105 (1989)
11. Ford, J. M.; Bruggeman, E. P.; Pastan, I.; Gottesmann, M.; Hait, W. N.: Cancer Res. 50, 1748 (1990)
12. Ramu, A.; in: Kessel, D. (Ed.); Resistance to Antineoplastic Drugs, p. 63, CRC, Boca Raton, Florida 1989
13. Ramu, A.; Ramu, N.: Cancer Chemother. Pharmacol. 30, 165 (1992)
14. Klopman, G.; Srivastava, S.; Kolossvary, I.; Epand, R. F.; Ahmed, N.; Epand, R. M.: Cancer Res. 52, 4121 (1992)
15. Liu, Q.; Hirono, S.; Moriguchi, I.: Chem. Pharm. Bull. 38, 2184 (1990)
16. Sylte, L; Dahl, S. G.: Pharm. Res. 8, 462 (1991)
17. Dahl, S. G.; Edvardsen, O.; Sylte, I.: Therapie 46, 453 (1991)
18. Dahl, S. G.; Kollman, P. A.; Rao, S. N.; Singh, U. C.: J. Comp.-Aided Mol. Design 6, 207 (1992)
19. Froimowitz, M.; Cody, V.: J. Med. Chem. 36, 2219 (1993)
20. Horwitz, J. P.; Massova, I., Wiese, T. E.; Besler, B. H.; Corbett, T. H.: J. Med. Chem. 37, 781 (1994)
21. Zamora, J. M.; Pearce, H. L.; Beck, W. T.: Mol. Pharmacol. 33, 454 (1988)
22. Pearce, H. L.; Safa, A. R.; Bach, N. J.; Winter, M. A.; Cirtain, M. C.: Proc. Natl. Acad. Sci. 86, 5128 (1989)
23. Pearce, H. L.; Winter, M. A.; Beck, W. T.: Adv. Enzyme Regulations 30, 357 (1990)
24. Klebe, G.; in: Kubinyi, H. (Ed.): 3D QSAR in Drug Design. Theory, Methods and Application, p. 173, Escom, Leiden, 1993
25. Wireko, F. C.; Kellogg, G. E.; Abraham, D. J.: J. Med. Chem. 34, 758 (1991)
26. Kellogg, G. E.; Abraham, D. J.: J. Mol. Graph. 10, 212 (1992)
27. Seydel, J. K., Velasko, M. A.; Coats, E. A.; Cordes, H.-P.; Kunz, B.; Wiese, M.: Quant. Struct.-Act. Relat. 11, 205 (1992)
28. Maurhofer, E.; Höltje, H.-D.: First Workshop on Molecular Modelling, May 1987, Darmstadt, Germany
29. Tnpos Ass., 1699 Hanley Road, St. Louis, Mo 63144, USA
30. Serena Software, P.O. Box 3076, Bloomington, Indiana 47402-3076, USA
31. Kellogg, G. E.; Semus, S. F.; Abraham, D. J.: J. Comput.-Aided Mol. Design. 5, 545 (1991)
32. Kellogg, G. E.; Joshi, G. S.; Abraham, D. J.: Med. Chem. Res. 1, 444 (1992)